Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    CEL-SCI Corporation

    AMEX: CVM · Real-Time Price · USD
    0.22
    -0.01 (-4.89%)
    At close: May 16, 2025, 3:59 PM
    0.22
    0.85%
    After-hours: May 16, 2025, 05:57 PM EDT
    -4.89%
    Bid 0.2
    Market Cap 20.3M
    Revenue (ttm) n/a
    Net Income (ttm) -20.04M
    EPS (ttm) -0.48
    PE Ratio (ttm) -0.46
    Forward PE -0.25
    Analyst n/a
    Ask 0.24
    Volume 1,586,345
    Avg. Volume (20D) 1,604,356
    Open 0.23
    Previous Close 0.23
    Day's Range 0.21 - 0.23
    52-Week Range 0.18 - 2.22
    Beta 0.50

    About CVM

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CVM
    Website n/a
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 months ago
    -32.26%
    Cel-Sci shares are trading lower after the company... Unlock content with Pro Subscription
    news image

    2 days ago · businesswire.com

    CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal second quarter 2025 financial results.

    news image

    3 weeks ago · businesswire.com

    CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market.

    news image

    1 month ago · businesswire.com

    New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--New study in the scientific journal “Cancer Cell” supports CEL-SCI's strategy to seek early approval for Multikine.

    news image

    1 month ago · businesswire.com

    CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck Cancer Patients.

    news image

    2 months ago · businesswire.com

    CEL-SCI Announces Closing of $2.5 Million Offering

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $2.5 million offering .

    news image

    2 months ago · businesswire.com

    CEL-SCI Announces Pricing of $2.5 Million Offering

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $2.5 million offering.

    news image

    2 months ago · businesswire.com

    Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

    news image

    2 months ago · businesswire.com

    CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial.

    news image

    2 months ago · businesswire.com

    CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows pre-surgical tumor elimination and regression in just 3 weeks.

    Add to Watchlist